Sildenafil and Pharma: A Risky Investment?

The history of the erectile dysfunction drug presents a intricate picture for investors. While the initial introduction generated significant profits, the end of its exclusive rights opened the door to cheaper versions, dramatically reducing revenue. This creates a specific dilemma for firms rely

read more